Structural basis of substrate-binding specificity of human arylamine N-acetyltransferases.

Article Details

Citation

Wu H, Dombrovsky L, Tempel W, Martin F, Loppnau P, Goodfellow GH, Grant DM, Plotnikov AN

Structural basis of substrate-binding specificity of human arylamine N-acetyltransferases.

J Biol Chem. 2007 Oct 12;282(41):30189-97. Epub 2007 Jul 26.

PubMed ID
17656365 [ View in PubMed
]
Abstract

The human arylamine N-acetyltransferases NAT1 and NAT2 play an important role in the biotransformation of a plethora of aromatic amine and hydrazine drugs. They are also able to participate in the bioactivation of several known carcinogens. Each of these enzymes is genetically variable in human populations, and polymorphisms in NAT genes have been associated with various cancers. Here we have solved the high resolution crystal structures of human NAT1 and NAT2, including NAT1 in complex with the irreversible inhibitor 2-bromoacetanilide, a NAT1 active site mutant, and NAT2 in complex with CoA, and have refined them to 1.7-, 1.8-, and 1.9-A resolution, respectively. The crystal structures reveal novel structural features unique to human NATs and provide insights into the structural basis of the substrate specificity and genetic polymorphism of these enzymes.

DrugBank Data that Cites this Article

Polypeptides
NameUniProt ID
Arylamine N-acetyltransferase 2P11245Details
Arylamine N-acetyltransferase 1P18440Details